Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma (DMV)

This study has been withdrawn prior to enrollment.
(low accrual)
Sponsor:
Information provided by:
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT00516191
First received: August 13, 2007
Last updated: June 21, 2011
Last verified: June 2011

August 13, 2007
June 21, 2011
October 2004
October 2010   (final data collection date for primary outcome measure)
--To evaluate the safety and tolerability of four dose levels of liposomal doxorubicin, melphalan, and bortezomib in patients with relapsed/refractory MM and to identify a maximum tolerated dose of this combination. [ Time Frame: 6 years ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00516191 on ClinicalTrials.gov Archive Site
--To determine the efficacy of DMV therapy --Tabulate all the toxicities of DMV at the MTD by NCI criteria [ Time Frame: 6 years ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma
A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma

The primary objective of this study is to evaluate the safety and tolerability of four dose levels of liposomal doxorubicin, melphalan, and bortezomib in patients with relapsed/refractory MM and to identify a maximum tolerated dose (MTD) of this combination.

Not Provided
Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Multiple Myeloma
Drug: Liposomal Doxorubicin/Melphalan/Bortezomib

Day 1 Bortezomib 0.7 mg/m(2)IV + Doxil 10-20 mg/m(2)IV+Melphalan 5-10mg/m(2)IV Day 4 Bortezomib 0.7 mg/m(2)IV Day 8 Bortezomib 0.7 mg/m(2)IV Day 11 Bortezomib 0.7 mg/m(2)IV

The treatment cycles will be repeated every 28 days. Dose Level 1: Doxil 10mg/m(2), Melphalan 5 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 2: Doxil 10mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 3: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 4: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 1.0mg/m(2)

Other Names:
  • Liposomal Doxorubicin=Doxil
  • Melphalan=Alkeran
  • Bortezomib=Velcade
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
30
December 2010
October 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Previously diagnosed with multiple myeloma; Durie-Salmon Stage I, II, or III based on standard criteria
  • Progressive disease, defined as 25% increase in serum M-protein or Bence Jones protein (an absolute increase of 0.5 gram/dL serum M-protein or at least 200 mg/24 hours of urine light chain excretion). For non-secretory multiple myeloma, progressive disease is defined as bone marrow biopsy with >25% increase in plasma cells or an absolute increase of at least 10% over prior known level. Alternatively, development of new or worsening of existing lytic bone lesions or soft tissue plasmacytomas, or hypercalcemia or relapse from CR.
  • 18 year or older and willing and able to comply with the protocol requirements.
  • Patient has signed informed consent.
  • Unless a female patient is post-menopausal or surgically sterilized, must be willing to use an acceptable method of birth control (hormonal contraceptive, intrauterine device, diaphragm, with spermicide, condom with spermicide, or abstinence) for the duration of the study.
  • Male patient must agree to use an acceptable method for contraception for the duration of the study.
  • ECOG performance Status of < or equal to 2.
  • Life expectancy is at least 3 months.
  • Initial Required Laboratory Values within 14 days of baseline i.e. Cycle 1, Day 1 (note that renal insufficiency, including dialysis dependence is permissable):

    • ANC>1,000uL without the use of colony stimulating factors
    • Platelets >50,000/L without transfusion support 7 days before the test
    • Bilirubin < or equal to 2.0 mg/dL
    • AST < or equal to 4 x upper limit of normal
  • Prior therapy: Patient must have had at least 2 prior therapeutic regimens as defined below for treatment of multiple myeloma

    • Biologic therapy:
  • Prior nonmyeloablative transplantation allowed provided patient does not have significant graft-versus-host disease and is off aggressive immunosuppressive therapy for at least 30 days. Low dose immunosuppression is allowed (i.e. Prednisone at dose < or equal to 10 mg daily, low dose tacrolimus (subtherapeutic levels) or other agents with equivalent low-dose immunosuppression).

    • Chemotherapy:
  • Mobilization with chemotherapy followed by either single or tandem autologous transplantation is counted as 1 prior regimen.
  • Mobilization with chemotherapy followed by autologous and subsequent nonmyeloablative allogenic transplantation is counted as 1 prior regimen.
  • Any combination of drugs given concurrently is counted as a single regimen.

Exclusion Criteria:

  • Pregnant or breast-feeding
  • History of allergic reaction to compounds containing boron or mannitol.
  • Active uncontrolled viral (including HIV), bacterial, or fungal infection.
  • Grade III or IV toxicity due to previous anti-neoplastic therapy (except alopecia).
  • Grade > or equal to 2 motor or sensory neuropathy as defined by the NCI Common Toxicity Criteria (NCI CTC):
  • Grade 2: Either mild objective weakness or objective sensory loss/parasthesia (including tingling) that interferes with function, but not interfering with ADLs.
  • Grade 3: Objective weakness or sensory loss/parasthesia interfering with ADLs.
  • Grade 4: Paralysis or permanent sensory loss that interferes with function.
  • Myocardial infarction within 6 months of enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled arrhythmias, or electrocardiographic evidence of acute ischemia.
  • For any patients whose lifetime cumulative doxorubicin dose exceeds 400 mg/m(2), patients with LVEF < or equal to 35% by MUGA are excluded. In other patients, MUGA is not required but if performed, LVEF must be > or equal to 35%.
  • Concurrent administration of liposomal doxorubicin, melphalan, and bortezomib (single or two drug combinations of these are permissable).
  • Less than 3 weeks since most recent chemotherapy or concurrent chemotherapy.
  • Use of corticosteroids (>10 mg prednisone/day or equivalent).
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00516191
UC-2408
Yes
Thomas Martin, MD, Assistant Clinical Professor Medicine, University of California San Francisco
University of California, San Francisco
Not Provided
Principal Investigator: Thomas G. Martin, M.D. University of California, San Francisco
University of California, San Francisco
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP